- Home
- CGC vs INBX Comparison
CGC vs INBX Comparison
Compare CGC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- INBX
- Stock Information
- Founded
- CGC N/A
- INBX 2010
- Country
- CGC Canada
- INBX United States
- Employees
- CGC N/A
- INBX N/A
- Industry
- CGC Pharmaceuticals and Biotechnology
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- CGC Health Care
- INBX Health Care
- Exchange
- CGC Nasdaq
- INBX Nasdaq
- Market Cap
- CGC 311.8M
- INBX 341.2M
- IPO Year
- CGC N/A
- INBX 2020
- Fundamental
- Price
- CGC $1.30
- INBX $23.33
- Analyst Decision
- CGC Hold
- INBX Hold
- Analyst Count
- CGC 1
- INBX 1
- Target Price
- CGC N/A
- INBX N/A
- AVG Volume (30 Days)
- CGC 21.1M
- INBX 101.4K
- Earning Date
- CGC 08-08-2025
- INBX 08-13-2025
- Dividend Yield
- CGC N/A
- INBX N/A
- EPS Growth
- CGC N/A
- INBX N/A
- EPS
- CGC N/A
- INBX N/A
- Revenue
- CGC $201,572,742.00
- INBX $1,400,000.00
- Revenue This Year
- CGC $2.45
- INBX N/A
- Revenue Next Year
- CGC $3.66
- INBX N/A
- P/E Ratio
- CGC N/A
- INBX N/A
- Revenue Growth
- CGC N/A
- INBX N/A
- 52 Week Low
- CGC $0.77
- INBX $10.81
- 52 Week High
- CGC $7.21
- INBX $25.29
- Technical
- Relative Strength Index (RSI)
- CGC 51.99
- INBX 61.05
- Support Level
- CGC $1.02
- INBX $20.55
- Resistance Level
- CGC $1.81
- INBX $24.48
- Average True Range (ATR)
- CGC 0.14
- INBX 1.49
- MACD
- CGC 0.05
- INBX -0.10
- Stochastic Oscillator
- CGC 36.48
- INBX 58.65
About CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.